CCS
LGND icon

Crosspoint Capital Strategies’s Ligand Pharmaceuticals LGND Stock Holding History

Crosspoint Capital Strategies’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-170
Closed -$11K – 842
2015
Q2 		$11K Buy
+170
New +$9.28K ﹤0.01% 487
2014
Q2 		– Sell
-200
Closed -$8K – 578
2014
Q1 		$8K Buy
+200
New +$8.34K ﹤0.01% 500

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crosspoint Capital Strategies's LGND Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 170 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in LGND in Q1 2014 and held it in 2 quarters. The position peaked at $11K in Q2 2015. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 170 Ligand Pharmaceuticals shares in Q3 2015, an estimated $11K.
  • Crosspoint Capital Strategies first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Ligand Pharmaceuticals position peaked at $11K in Q2 2015.
  • 203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.